Key points are not available for this paper at this time.
Guadecitabine in combination with pembrolizumab is tolerable with biological and anticancer activity. Reversal of previous resistance to immune checkpoint inhibitors is demonstrated.
Papadatos-Pastos et al. (Wed,) studied this question.